Insight
Practical strategies for mitigating assay-driven stability artifacts in ligand binding ADC PK analysis
Unexpected assay variability can compromise confidence in ADC pharmacokinetic (PK) data. Discover how IQVIA Laboratories experts identified the root cause of concentration-dependent bias in a ligand binding assay and developed an innovative strategy to restore stability, improve assay performance and support reliable ADC bioanalysis.
Complete the form below to access this case study and view the original scientific poster to see how this innovative solution was developed.
Related Insights
ADME Services
Accelerating your drug discovery, preclinical and clinical programs
Bioanalytical Automation of Samples
Taking an assay from bench to an automated platform
Bioanalytical Automation of Samples
Taking an assay from bench to an automated platform
Developing Assays for Novel Drugs
Current science regarding hybrid assays, why they are considered the next "big thing," the technical challenges, and the regulatory impact of these assays.
Strategies for Effective Neutralizing Cell Based Assays in Early Immunogenicity Risk Assessment
Quantitative Assays for Peptides using LC-MS
Quantitative high-throughput analysis of peptide therapeutics and biomarkers to regulated bioanalytical standards
Hybrid Assays for Protein Bioanalysis
Assays and Why Are They Essential for Protein Bioanalysis?
Bioanalysis for Immuno Oncology with Mike Brown
I-O clinical development podcast series
IQVIA Laboratories Corporate Brochure
A global drug discovery and development laboratory services organization
Assay Development for Large-Scale Clinical Studies
Bioanalytical expertise to support large-scale, international studies
